ReviewJournal of pharmacy & bioallied sciences2025
A Review Article on Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Alzheimer's Disease.
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cognitive Impairment Associated with Chemotherapy: Neuroimmunological Interactions, Gut-Brain Axis, and Therapeutic Approaches.Brain sciences · 2026Review
- Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.Neurology international · 2026Review
- Oxidative Stress, Advanced Glycation End Products (AGEs), and Neurodegeneration in Alzheimer's Disease: A Metabolic Perspective.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid-beta plaque and tau tangle buildup lead to Alzheimer's disease (AD), a brain disorder that causes ongoing mental decline. More and more studies show that oxidative stress plays a crucial role in how AD develops and progresses. This review focuses on presenilin-1 (PSEN1) and F2-isoprostanes, two key indicators of oxidative stress. F2-isoprostanes, which come from damaged fats, appear in much higher levels in people with AD. These substances link to more brain inflammation, nerve cell death, and problems with thinking and memory. Processing of the amyloid precursor protein is dependent on presenilin-1, one of the main components of the γ-secretase complex. It has been shown that mutations in PSEN1, an important gene for familial AD, augment oxidative stress and malfunction of mitochondria, which further aggravates neuronal damage. In this article, the role of F2-isoprostanes and PSEN1 in oxidative stress pathways leading to AD and how their interaction makes the disease worse has been investigated. The contribution of presenilin-1 (PSEN1) and oxidative stress markers, such as F2-isoprostanes, to AD underscores a crucial link in understanding such a complex neurodegenerative pathology. F2-isoprostanes are valuable biomarkers of oxidative stress linked to the severity of illness and cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.